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Abstract 
Cell death results in tissue damage and ultimately donor graft rejection and can occur as an 
active molecular process through apoptotic, necrotic and newly identified Receptor 
Interacting Protein 1 and 3 kinase (RIPK1/3) mediated necroptotic pathways. Necroptosis 
leads to the release of inflammatory molecules and activation of immune cells which can 
potentially threaten the graft and has yet to be studied in cardiac transplantation. We have 
found that necroptosis was induced in murine cardiac microvascular endothelial cells 
(MVEC) under anti-apoptotic conditions following TNFα treatment and results in the release 
of the danger molecule high mobility group box 1 (HMGB1). Necroptosis was inhibited by 
the RIPK1 inhibiting molecule necrostatin-1 and by genetic deletion of RIPK3. In addition, 
tissue necrosis, release of HMGB1 and graft cell infiltrate were attenuated in RIPK3 null 
heart allografts following transplantation. Finally, a brief sirolimus treatment markedly 
prolonged RIPK3 null cardiac allograft survival in allogeneic BALB/c recipients as 
compared to wildtype C57BL/6 donor grafts (95+5.8 vs. 24+2.6 days, P<0.05). This study 
has demonstrated that RIPK1/3 contributes to MVEC death and cardiac allograft survival 
through necroptotic death and the release of danger molecules. Our results suggest that 
targeting RIPK-mediated necroptosis may be an important therapeutic strategy in 
transplantation. 
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Chapter 1  
1 Introduction 
1.1   Current status of cardiac allograft transplantation 
Following irreversible cardiac damage, transplantation is the most beneficial and highly 
pursued treatment option available. Cardiac transplantation is most commonly used to 
treat diseases related to cardiomyocyte dysfunction, coronary artery disease, congenital 
defects and valvular dysfunction1. In past decades, advances in therapeutic 
immunosuppression and biopsy techniques have allowed adequate control of host 
immune cell-mediated rejection, improving heart allograft half-life times from 9.6 years 
in 1982-1992, to 12.0 years in 1993-20031. However, following 2003, improvements in 
heart transplant survivability have been the result of enhanced one-year survival due to 
superior therapeutic management of acute rejection, rather than novel chronic rejection 
therapy, as indicated by conditional post-one-year survival rates1. The understanding of 
the mechanisms involved in chronic rejection of heart allografts continues to fall behind 
that of acute rejection, necessitating further research in the chronic rejection field. 
 
1.2 Cardiac allograft rejection 
Transplantation invariably results in organ injury mediated by host immune cell 
activation and graft infiltration. Nearly every branch of the immune system has been 
implicated in allograft rejection, including innate immunity2, 3, antibody mediated 
rejection (AMR) resulting in hyperacute accelerated graft rejection and chronic 
rejection4, and alloimmune recognition of donor MHC/HLA resulting in adaptive 
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immune responses. Each of these branches poses a threat to the graft independently and 
collectively. 
 
Acute cellular rejection (ACR) in cardiac grafts is predominantly a T-cell mediated 
response characterized by the infiltration of lymphocytes and macrophages into the graft 
followed by myocyte necrosis and eventual loss of graft function. Host immune cell 
infiltration can be focal or diffuse depending on the rejection grade defined by the 
International Society of Heart and Lung Transplantation (ISHLT). ISHLT grading spans 
from Grade 1, characterized by perivascular or interstitial infiltration with up to one focus 
of myocyte damage, to Grade 4, characterized by diffuse polymorphous infiltrate with 
extensive myocyte damage, edema, hemorrhage and vasculitis5, 6.  According to the 
current models of ACR pathogenesis, ACR is initiated by the maturation of recipient 
CD4+ T helper cells, CD8+ cytotoxic T cells and the transformation of host B 
lymphocytes into antibody producing plasma cells. These cell types can attack the graft 
directly or indirectly through inflammatory responses that involve monocytes and 
macrophages. This process is orchestrated by soluble cytokines, such as Tumor Necrosis 
Factor α (TNFα)7, that can activate host immune cells or initiate cell death in target cells. 
Clinically, over 60% of patients will experience one or more acute rejection episodes 
within 6 months of transplantation. However, due to the advancement of biopsy 
techniques and immunosuppressive management, acute rejection survival rates have 
drastically improved1. 
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In contrast to ACR, chronic cardiac allograft rejection presents as severe, diffuse vascular 
intimal hyperplasia involving the entire vessel wall, often resulting in compromised 
vascular flow and eventual ischemia, similar to non-transplant atherosclerosis. This 
phenomenon is known as Graft Vascular Disease (GVD). Although the pathogenesis of 
GVD is not fully understood, the process is known to be mediated by the diffuse 
accumulation of smooth muscle cells within the vessel intima in response to vascular 
damage. In the early stages of developing GVD lesions, subendothelial accumulation of 
mononuclear inflammation occurs in conjunction with increased markers of endothelial 
cell (EC) activation8, 9. As a result of low-level injury caused by recipient infiltrate, host 
immune cells as well as dysfunctional graft endothelial and smooth muscle cells secrete 
growth factors to recruit and activate smooth muscle cells8, 10, 11. Interestingly, the 
mechanism of vascular damage seems to be irrelevant in the progression of GVD. Indeed, 
non-immune graft injury such as IRI can exacerbate GVD through endothelial necrosis, 
resulting in danger molecule release12 and EC activation9, 13, 14. Interestingly, intimal 
thickening does not cross the suture line between graft and host vessels, implying an 
alloimmune role also exists in the pathogenesis of GVD. CD4+ T cells have been 
indirectly implicated in the progression of GVD through the disruption of nitrous oxide 
production in ECs by interferon γ (IFNγ) release15 and cytokine/chemokine regulation by 
TNFα16 after activation by antigen presenting cells (APC). Although it is unlikely that 
any single mechanism causes GVD, the incidence of GVD correlates with CD4+ T cell 
presence with indirect antidonor allospecificity17, suggesting that indirect allorecognition 
is the major pathway of GVD development18. In contrast with ACR, GVD is 
unresponsive to immunosuppressive treatment due to the plethora of biological 
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mechanisms resulting in its pathogenesis. Consequently, GVD is currently the limiting 
factor of cardiac allograft transplantation and future therapies, such as the one described 
here, may instead rely on preventative treatment and endothelial preservation to extend 
graft survival times.  
 
Currently, several immunosuppressive methods exist to prevent cellular and antibody 
mediated rejection. As mentioned, T cells often play a critical role during immune 
responses against the allograft19. In order to achieve T cell activation, several molecular 
pathways must be activated. These include antigen recognition through the T cell 
receptor (TCR) (signal 1), verification by co-stimulators (signal 2), and cytokine 
(particularly IL-2) induced proliferation and maturation. Many immunosuppressive 
therapies target these pathways by preventing either APC activation or lymphocyte 
activation and proliferation. 
 
During immune reactions, T cells recognize foreign antigens presented on APCs using a 
TCR/CD3 protein complex. To achieve T cell activation, survival and clonal expansion, 
an additional signal, known as a costimulatory signal, must also be provided. Failure to 
provide this signal will result in T cell anergy20. Several transplant-relevant costimulatory 
receptors and ligands have been identified21. These include the CD28/B7 pathway and the 
CD40/CD154 pathway. The CD28/B7 costimulatory pathway is one of the most 
important T cell activation pathways in both mice and humans and activation failure of 
this pathway results in T cell anergy, rendering T cells functionally inactive22, 23. Upon 
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engagement with its ligands B7.1 (CD80) and B7.2 (CD86), CD28 initiates a T cell 
activation signal, allowing for T cell survival, proliferation and cytokine production. This 
activation pathway is negatively regulated by the CD28 analog cytotoxic T-lymphocyte-
associated-antigen 4 (CTLA4), which is also expressed on the surface of T cells. CTLA4 
binds B7.1 and B7.2 with greater affinity than CD28 and down-regulates T cell 
responses24, 25 and knockout of either CTLA4 or CD28 results in severe 
lymphoproliferative disorders. Blockade of CD28 directly results in unwanted clinical 
side effects and therefore an antibody fusion protein CTLA4Ig is instead used to inhibit 
CD28 activation26. Another important costimulatory pathway involves CD40 and CD154 
interaction. CD40 is a TNFR superfamily member and is expressed on the surface of 
APCs. Binding of CD154 on T cells to CD40 is critical for dendritic cell (DC) activation 
and upregulation of MHC, B7 molecules and cytokine production27. CD40/CD154 
activation is important during plasma cell isotype switching28, and indirect activation of T 
cells through the promotion of CD80 or CD86 expression29. This pathway can be 
inhibited using an anti-CD40 antibody, preventing CD40/CD154 binding, and has shown 
efficacy in extending allograft survival but not in preventing GVD30. 
 
Lastly, T cell specific immunosuppression can be achieved by inhibiting IL-2 cytokine 
production. The advent of the calcineurin inhibitors cyclosporine and tacrolimus, which 
bind cytosolic proteins cyclophilin and FK binding protein 12 (FKBP12) respectively, 
greatly advanced the field of transplantation in the 1980’s. Binding of cyclophilin and 
FKBP12 inhibits calcineurin phosphatase, preventing transcription of cytokines 
(including IL-2) and T cell expansion.  Sirolimus, which has a similar molecular structure 
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to tacrolimus, also binds to FKBP12 but does not inhibit calcineurin phosphatase. 
Instead, sirolimus binds to the mammalian target of rapamycin (mTOR), a downstream 
effector of both the CD28/B7 costimulatory pathway and IL-2, effectively making 
sirolimus an inhibitor of both signal 2 and signal 331. In this study, both sirolimus and 
CD40 costimulatory blockade are used to promote allograft tolerance. 
 
1.3 Immunophysiology of endothelial cells in transplantation 
Microvascular endothelial cells (MVEC) are the first barrier between the graft and host 
after any solid organ transplantation. Consequently, MVECs are a key player during graft 
recognition by host immune cells and organ rejection. MVEC activation has been shown 
to be an important factor in transplantation and can result from donor brain death32, 
ischemia reperfusion injury (IRI)33, 34, cyclosporine toxicity35 and, most importantly, host 
immune responses to donor antigens.   
 
Following their activation, MVECs mediate graft injury directly or indirectly through 
platelet adhesion, increased vascular permeability, expression of adhesion molecules and 
the release of proinflammatory molecules, such as TNFα or interleukin 1 (IL-1), leading 
to a loss of vascular integrity and enhanced tissue damage36. These mechanisms may 
provide the first trigger of graft injury, resulting in increased host immune infiltration and 
accelerated graft rejection. 
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 Interestingly, cultured human MVECs have been shown to cause direct activation and 
proliferation of T cells in the absence of professional APCs through the expression of 
active costimulatory molecules such as CD4037 and promote the differentiation of 
monocytes into competent APCs38. Activation of CD4+ T cells induces expression of 
HLA class-II molecules on MVECs through IFNγ production, eliciting a sustained 
alloimmune reaction39 similar to delayed-type hypersensitivity reactions. MVECs also 
contribute to GVD and smooth muscle cell recruitment both directly and indirectly. 
Expression of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and the E and P-selectins on MVECs has been directly correlated 
to rejection and GVD40, 41 as expression of these molecules allows for adhesion and 
rolling of host leukocytes on the EC barrier of the graft. Lastly, as previously mentioned, 
EC dysfunction can exacerbate GVD through growth factor and danger molecule release. 
As the first biological barrier between graft and host and a key mediator of lymphocyte 
activation, ECs play an important role in alloimmune responses following cardiac 
transplantation. 
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An artery consists of several anatomical structures including the endothelium, intimal 
region, smooth muscle layer and is surrounded by connective tissue. The endothelial 
layer interacts with blood cells in the serum and plays important roles in facilitating white 
cell emigration from the blood into the tissue. In transplantation, the endothelial lining 
serves as the barrier between the graft and the host, making it an important player in 
immune responses against the graft.  
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Figure 1 – Anatomy of an artery 
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1.4 TNFα and TNFα receptors 
TNFα, also known as cachectin, was originally identified as a potent inducer of cell death 
in tumour cells42 but is recognized today as a pleotropic cytokine involved in many signal 
transduction pathways including cell survival, proliferation, activation and cell death. 
TNFα has been shown to be an important contributor to heart graft rejection and GVD 
through the regulation of soluble TNFα43 and TNFα receptors44. Furthermore, TNFα has 
implicated in the induction of early neutrophil and macrophage chemoattractant levels, 
increased immune cell infiltrate45 and decreased graft survivability46, 47 following cardiac 
transplantation.   
 
As suggested above, TNFα can induce a variety of cellular responses. Traditionally, 
TNFα was thought to induce programmed apoptosis in target cells following TNFα 
Receptor (TNFR) 1 binding, or immune activation through transcription factor NF-κB 
following TNFR2 signalling7. Interestingly, human and murine MVECs in heart grafts 
constitutively express diffuse levels of death receptor TNFR1 and activating receptor 
TNFR2 before and after transplantation48. Conversely, cardiomyoctytes, which normally 
express high levels of TNFR1, drastically reverse TNFα receptor expression from 
TNFR1 to TNFR2 following rejection injury44, 48. This suggests that human and murine 
MVECs in donor grafts may be more vulnerable to TNFα mediated death than 
cardiomyocytes. Recently, TNFα has been shown to also initiate a second cell death 
pathway known as necroptosis, also initiated through TNFR149, 50.  
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1.5 Apoptosis, necrosis and necroptosis 
Cell death has been classified into a variety of forms including apoptosis, necrosis, post-
apoptotic secondary necrosis, necroptosis, autophagy and mitotic catastrophe51. The two 
extremes in the array of cell death are caspase-dependent apoptosis and caspase-
independent necrosis. Apoptosis is characterized by DNA fragmentation and membrane 
blebbing induced by endogenous nucleases, whereas necrosis is characterized by swelling 
of the mitochondria and cytoplasm, due to ATP depletion, leading to eventual plasma 
membrane rupture and lysis of the cell.  
 
Traditionally, apoptosis was viewed as the primary active and programmed form of cell 
death while necrosis was viewed as a passive and immunogenic form of cell death. 
However, this paradigm has been challenged in recent years with the discovery of 
necroptotic cell death, which takes on characteristics of both apoptosis and necrosis. Like 
apoptosis, necroptosis requires endogenous cellular machinery to initiate cell death. This 
process is initiated through either TNFR149, tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL)52, 53, Fas54, Toll-like receptor (TLR) 355 or 456, or retinoic acid-
inducible protein57 signalling. The result is the activation of receptor interacting protein 
kinase (RIPK) 1 and RIPK3, together known as the necrosome, which induce necrotic-
like cell death through endogenous reactive oxygen species (ROS) production.  
 
TNFα mediated death signalling requires the formation of a complex of proteins on the 
inner membrane domain of TNFR1 known as Complex I (Figure 1). This complex 
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includes TNFα receptor associated death domain (TRADD), TNFα receptor associated 
factor (TRAF), cellular inhibitors of apoptosis (cIAP) 1 and 2, and poly-ubiquitinated 
RIPK1. Binding of NF-kappa B essential modulator (NEMO) to the ubiquitin tail of 
RIPK1 will result in the downstream activation of NF-κB, mitogen-activated protein 
kinase (MAPK) and c-Jun N-terminal kinases (JNK), resulting in survival of the cell. 
Alternatively, deubituitination of RIPK1 by enzymes A20 or cylindromatosis (CYLD) 
will result in formation of complex II, which includes RIPK1, RIPK3, TRADD and the 
Fas Associated Death Domain (FADD)58-60. Caspase-8 recruitment into Complex II will 
result in the cleavage of RIPK1 and RIPK3 followed by caspase-8 mediated apoptosis. In 
the absence or inhibition of caspase-8, RIPK3 will autophosphorylate itself and 
phosphorylate RIPK1, initiating a downstream cascade resulting in up-regulation and 
activation of three metabolic enzymes: Glutamine Synthase (GLUL), Glutamate 
Dehydrogenase (GLUD1) and Glycogen Phosphorylase (PYGL)50, 60. PYGL is 
responsible for the catabolism of glycogen to glucose-1-phosphate, directly fuelling 
glycolysis, while GLUL catabolises glutamate to glutamine, stimulating gluconeogenesis, 
glutathione production and lipogenesis. GLUD1 is subsequently involved in glutamine 
catabolism, increasing the cellular pool of α-ketoglutarate to feed the TCA cycle.  RIPK 
mediated increases in cellular energy metabolism through activity of these enzymes 
results in excessive reactive oxygen species (ROS) production within the mitochondria, 
eventually resulting in cytotoxicity of the cell61. Indeed, mitochondrial derived ROS have 
been implicated in the ultrastructural changes seen in cellular organelles during 
programmed necrosis62. This provides strong evidence that the current model of TNFα 
induced necroptosis is mediated through increased ROS production. Consequently, like 
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traditional necrosis, necroptosis is considered to be immunogenic, potentially making it 
an important player during transplantation. 
 
1.6 Inhibiting TNFα mediated cell death 
The discovery of TNFα mediated necroptosis lead to the discovery of chemical 
compounds that allosterically inhibited the kinase activity of RIPK1, known as 
necrostatins63, 64. These compounds do not affect the activation of NF-κB, MAPK or JNK 
signalling following TNFR1 activation, confirming the bifurcation between cell survival 
and cell death following TNFR1 activation. Necrostatins have been shown in 
experimental models to be beneficial inhibitors of cell death following ischemic brain 
injury63, myocardial infarction65 and chemotherapy-induced cell death66. Conversely, 
because the induction of TNFα mediated necroptosis is dependent on caspase-8 
inactivity, compounds that inhibit caspase-8, such as the pan-caspase inhibitor zVAD-
fmk, can be used to induce necroptosis following TNFα treatment60. zVAD-fmk works 
by binding the active site of caspase-867, preventing caspase-8-ligand interactions.  
 
Although synthetic caspase inhibitors such as zVAD-fmk do not exist in biological 
systems, caspase inhibition can occur naturally in a variety of instances. In fact, simple 
changes in the redox status of the active cysteine residue in the caspase active site can 
render caspase activation impossible68. A study by Cho and colleagues has also revealed 
that TNFα treated cells infected with vaccinia virus, which encodes the viral caspase 
inhibitor Spi2, also undergo necroptosis and knockout of RIPK3 in this model results in 
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higher vaccinia virus titers compared with wildtype mice69. This data implies that RIPK 
signalling likely has a physiological role as a backup mechanism in viral protection 
where the viral target is caspase-8. This protective effect is then amplified by the release 
of cellular danger associated molecular patterns (CDAMPS) following necroptosis, which 
attract and activate the innate and adaptive immune system70. Interestingly, it seems that 
some viruses, such as cytomegalovirus (CMV), have evolved to escape this mechanism. 
CMV does this through expression of viral proteins M36, an inhibitor of caspase-8 
activation71, and M45, an adaptor protein that interferes with RIPK1 and RIPK3 
interaction72 and NF-κB activation73, rendering TNFR1 signaling inert. Physiologically, 
necroptosis appears to be another player in the biological arms race between infecting 
organisms and the immune system. 
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TNFα initiates necroptosis through binding of TNFR1. Following this, an intracellular 
complex forms on the innermembrane domain of the TNFR1 receptor, including 
polyubiquitilylated RIPK1. Binding of NEMO to the ubiquitin tail of RIPK1 results in a 
downstream pathway activating NFκB. Alternatively, enzymes A20 or CYLD 
deubiuinate RIPK1, which associates with RIPK3 to form the necrosome. Caspase 8, if 
present, will cleave the necrosome and initiate caspase-dependent apoptosis. If caspase 8 
is absent or inhibited, the necrosome will autophosphorylate and activate downstream 
enzymes, initiating necroptosis.  
Figure 2 – The mechanism of TNFα mediated necroptosis 
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1.7 Inflammatory implications of cell death 
Apoptotic death prevents the release of cell contents and can minimize inflammation, 
whereas necrosis results in the release of pro-inflammatory CDAMPs, including high 
mobility group box 1 (HMGB1), heat shock protein (HSP), RNA, DNA, fibronectin, and 
uric acid74, 75. These released danger molecules promote inflammatory responses through 
interactions with TLRs and other innate receptors74-76. In transplantation, TLR 
engagement has been found to accelerate vascular allograft rejection77-79, making 
proinflammatory CDAMPs such as HMGB1, which are only released following cell 
lysis, a powerful marker for necroptosis75. Indeed, necroptosis has been implicated in a 
variety of diseases resulting in CDAMP release including cerulean-induced pancreatitis60, 
80
, cerebral cortex infarction63, chronic intestinal inflammation81, systematic 
inflammatory response syndrome82, myocardial infarction65, 83 and IRI in the kidney84, 85 
and heart86, 87.  Distinguishing these mechanisms of cell death could be crucial in 
transplantation as necroptosis is phenotypically similar to necrosis and may play a central 
role in allograft rejection by enhancing the release of proinflammatory danger molecules 
and promoting inflammatory injury in the graft.  
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HMGB1, a nuclear protein involved in chromatin architecture, is a potent immunogenic 
CDAMP. During apoptosis, HMGB1 is oxidized and sequestered to the nucleus where it 
is rendered inactive. However, during necrosis or necroptosis, active HMGB1 is released 
from the cell where it will interact with TLRs and RAGE receptors on immune cells, 
initiating an immune response. 
 
 
 
 
 
Healthy Cell 
Apoptosis 
Necrosis 
 
Cytoplasm/ 
Plasma membrane 
Nucleus HMGB1 
Figure 3 – HMGB1 release following necrotic cell death 
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1.8 Hypothesis 
We hypothesize that the pattern of cell death in the graft following cardiac transplantation 
affects graft survivability as necrotic or necroptotic death will lead to exacerbated 
inflammation and accelerated graft rejection. 
 
 
Figure 4 – Necrostatin-1 or RIPK3 knockout will prevent exacerbation of 
inflammation 
Following cardiac transplantation, inflammation will lead to graft immune cell infiltration 
and the release of TNFα. In wild type mice, heart cells will be susceptible to 
RIPK1/RIPK3 mediated necroptosis, which leads to the release of the immunogenic 
CDAMP HMGB1. This in turn leads to the activation of more host immune cells and 
further inflammation. Treatment with Nec-1 or knockout of RIPK3 prevents cells from 
undergoing RIPK1/RIPK3 mediated necroptosis, breaking the inflammatory cycle. 
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1.9 Specific aims 
1. To determine the effects of apoptosis and necroptosis on MVECs.  
2. To show that the inhibition of RIPK1 and RIPK3 function in MVECs results in 
decreased necroptotic death and subsequent danger molecule HMGB1 release.  
3. To determine if RIPK3 deficiency in donor heart grafts inhibits necroptosis and 
subsequently prolongs graft survival. 
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Chapter 2  
2 Materials and Methods 
2.1 Animals 
C57BL/6 (H-2b), BALB/c (H-2d) (Jackson Laboratories, Bar Harbor, ME), and B6 
RIPK3-/- mice (H-2b) (Genentech)88 were maintained in the animal facility at the Western 
University. All experimental procedures were approved by the Western University 
Animal Care Committee. 
2.2 Microvascular endothelial cell (MVEC) culture 
MVECs from mice hearts were isolated as previously described89 using anti-CD31 coated 
Dynal magnet beads (Invitrogen). MVECs were immortalized through transfection of 
origin-defective SV40 DNA90. Transfection was done using the calcium-phosphate co-
precipitation method (Invitrogen). Cells were grown in complete EGM-2 MV containing 
5% FBS, 0.04% hydrocortisone, 0.4% hFGF-b, 0.1% VEGF, 0.1% R3-IFG-1, 0.1% 
Ascorbic acid, 0.1% hEGF and 0.1% GA-1000 (Lonza). MVEC phenotype was 
confirmed by staining with anti-CD31, CD102 and CD105 (eBioscience). Cells were 
passaged a maximum of 10 times before being discarded. 
2.3 Heart transplantation 
BALB/c mice (H-2d) were transplanted with heterotopic hearts from either C57BL/6 or 
B6 RIPK3-/- (H-2b) mice. Ischemic time was limited to 15 minutes during all 
transplantations. The donor heart was anastomosed via the donor aorta to the recipient 
abdominal aorta and donor pulmonary artery to recipient inferior vena cava using 
microsurgical techniques. The donor vena cava and pulmonary vein were sutured shut. 
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Following reperfusion, the heart grafts resumed spontaneous contraction. Recipients were 
treated daily with 1mg/kg sirolimus (LC Laboratories, Woburn, MA) from day 0 until 
postoperative day 991 or CD154 antibody (MR1) (200ug) one preoperative day before 
transplantation. The strength and quality of cardiac muscle contractions were monitored 
by palpation of the abdomen. Graft rejection (cessation of pulsation) was monitored daily 
after transplantation and confirmed by pathological analysis. 
2.4 In situ ethidium homodimer perfusion 
Recipient animals were anesthetized with the mixture ketamine/xylazine according to the 
approved animal protocol. The abdominal cavity was opened and the heterotopic heart 
was isolated from surrounding tissue. A blood sample was taken from the inferior vena 
cava above the left renal vein at this time. The inferior vena cava and dorsal aorta were 
then fully occluded just above and below the heterotopic heart using a microsurgical 
vascular clamp. The pulmonary artery of the donor heart was then cut to allow the 
perfusion solution to drain. A solution of 5 µM ethidium homodimer (Invitrogen) in 
saline was perfused into the aorta at 1 ml/min for 5 minutes92. Successful perfusion was 
observed by flushing of blood from the descending coronary arteries, expansion of the 
heterotopic heart and exit of perfusion solution from the pulmonary artery incision. 
Following this, saline was perfused at 1ml/min for 10 mins to flush excess and unbound 
ethidium homodimer. The heart was then removed and cut through the transverse plane 
before being put in formalin or liquid nitrogen.  
Tissues were analyzed and quantified for area and fluorescent intensity by a fluorescent 
microscope (NIS Elements 3.0, Nikon). Areas positive for necrosis were measured by 
ethidium homodimer labelled red fluorescence. 
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2.5 Western blot 
Supernatants were collected from equal number cell seeded wells for western blot 
analysis. Protein was isolated from heart tissue using cytoplasmic lysis buffer (10mM 
HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 0.1%NP40, 1mM DTT, 0.5mM 
PMSF) for non-nucleic protein analysis. Protein concentration was determined using Bio-
Rad Protein Assay (Bio-Rad) at 595nm on a spectrophotometer (Beckman Coulter). 
Sample buffer (2ME, glycerol, bromophenol blue, Tris-HCl) was added to the protein 
and was separated by gel electrophoresis by 4% resolving gel and 10% running gel. 
Protein was transferred to a nitrocellulose membrane using the iBlot dry transfer system 
(Invitrogen). Blots were blocked with 5% milk (Carnation) in Tris buffered saline and 
Tween 20 (TBS-T) and were incubated with polyclonal rabbit anti-RIPK3 (Abcam), 
rabbit anti-HMGB1 (Abcam), or mouse anti-β-actin (Sigma) in 2.5% milk TBS-T. 
Protein was visualized using secondary anti-rabbit IgG (Sigma) antibody with conjugated 
horseradish peroxidase and chemiluminescent HRP substrate (Millipore). Protein 
concentration was semi-quantitated by densitometry (Alpha View) and normalized using 
β-actin. 
2.6 RNA isolation and real-time PCR 
Total RNA was extracted from tissue or cells by Trizol extraction (Invitrogen).  cDNA 
was generated from RNA using Superscript II (Invitrogen).  Primers used for real time 
PCR include: RIPK3: 5’-GGGACCTCAAGCCCTCTAAC-3’ and 5’-
GATCCCTGATCCTGACCCTGA-3’. β-Actin: 5'-CCA GCC TTC CTT CCT GGG TA 
and 3'-CTA GAA GCA TTT GCG GTG CA. Real-time quantitative PCR was performed 
on standardized quantities of cDNA using the SYBR qPCR Master Mix kit (BioRad). 
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Gene amplification was performed and detected using the Mx3005 system (Stratagene). 
β-actin amplification was used as the endogenous control. The normalized delta threshold 
cycle value and relative expression levels (2-∆∆Ct) were calculated according to the 
manufacturer’s protocol.  
2.7 Cell death assay 
MVECs were grown to monolayer and treated with 100µg/ml of recombinant human 
TNFα (Peprotech) and 60µg/ml recombinant mouse IFNγ (Peprotech), 60 µM zVAD-fmk 
(BD Bioscience) and/or 10 µM necrostatin-1(Calbiochem) in serum free media for 48h. 
MVECs were trypsinized (Gibco) and washed with PBS. Cell death was detected with 
propidium iodide (P.I.) or annexin V labeling (BD Bioscience) and analyzed by flow 
cytometry (Beckman Coulter).  
2.8 Histology and immunohistochemistry 
Tissue sections were stored in 5% formalin (Sigma) and paraffin fixed and stained with 
hematoxylin and eosin (H&E). Slides were scored by a pathologist in a blinded fashion 
(0: no change, 1+: <25% area change, 2+: 25-50% area change, 3+: 50-75% area change, 
4+: 75% area change)91, 93. Criteria for allograft injury included endothelial cell damage, 
infarction, lymphocyte infiltrate, fibrosis, thrombosis, hemorrhage, myocyte damage and 
neutrophil infiltrate.  
RIPK3 and HMGB1 expression in the heart graft was detected by anti-RIPK3 (Abcam) 
or anti-HMGB1 (Abcam) by immunohistochemistry according to a standard protocol. 
Apoptosis in tissue was determined by TUNEL staining (Calbiochem). 
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2.9 Statistical analysis 
Data was compared using Student’s t-test for unpaired values. Graft survival was 
analyzed by log-rank testing (Mantel-Cox). Data was presented as mean ± standard 
deviation (SD) and p values < 0.05 were considered to be significantly different. 
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Chapter 3  
3 Results 
3.1 Isolation and characterization of MVECs 
MVECs were developed from C57BL/6 hearts as described in the methods. The 
phenotype of MVECs was confirmed by morphology (Figure 5A) and flow cytometry 
through CD3194, CD10295, and CD10596 positivity (Figure 5B). 
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Figure 5 – Isolation and characterization of MVECs 
A) MVECs were isolated using CD31 coated beads and immortalized with 
origin deficient SV40 DNA. Cells were grown in a monolayer analysed using 
confocal microscopy at 400X magnification. B) Cells were also analysed for 
the presence of the endothelial markers CD31, CD102 and CD105 by flow 
cytometry analysis. 
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3.2 RIPK3 and TNFR1 expression in MBECs are regulated 
by proinflammatory cytokines 
We first determined whether TNFR1 and RIPK3 expression can be regulated by 
proinflammatory cytokines in MVECs as TNFα mediated apoptotic or necroptotic cell 
death requires expression of death receptor TNFR1 and RIPK3. Expression of RIPK3 in 
MVECs was analyzed by qPCR after treatment with TNFα or IFNγ. Our data indicates 
that treatment with TNFα up-regulates RIPK3 mRNA expression in a dose dependant 
manner (Figure 6A). Significant differences were seen at treatments of 25ng/ml 
(mean+SD: 2.7 + 0.2 fold change, n=3, p<0.01) and 50 ng/ml of TNFα (12.5 + 1.6 fold 
change, n=3, p<0.05) compared to untreated MVECs. Expression of RIPK3 in MVECs 
was confirmed by western blot analysis (Figure 6B).  
 
Surface expression of TNFR1 on MVECs was determined by FACS analysis. As shown 
in Figure 6C, expression levels of TNFR1 on MVECs can be modulated by TNFα or 
IFNγ with maximum upregulation at 60ng/ml TNFα or IFNγ. Hence, proinflammatory 
cytokines can upregulate both TNFR1 and RIPK3 expression in MVECs.  
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Figure 6 - Expression of RIPK3 and TNFR1 in microvascular endothelial cells 
are upregulated by proinflammatory cytokines 
MVECs were isolated as described in the methods. A) MVECs were treated 
with 0, 25, 50 or 100 ng/ml TNFα for 48 hours in serum free EBM media. 
RIPK3 expressions were measured by real time qPCR as described in the 
methods. Β-actin was used as control (n=3, *: p < 0.05). B) RIPK3 protein was 
detected by western blot by anti-RIPK3 (Abcam) after 48 hour treatment with 
TNFα. C) Cells were treated with either 60 ng/ml TNFα or 60ng/ml IFNγ. 
Surface expression of TNFR1 on MVECs was measured using anti-TNFR1-PE 
(eBioscience) and analyzed by flow cytometry. 
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3.3 TNFα induces necroptosis in L929 cells under anti-
apoptotic conditions 
As previously described, L929 mouse fibroblasts are extremely susceptible to necroptotic 
death49. Before attempting to induce necroptosis in MVECs, L929 cells were treated with 
TNFα, zVAD-fmk and necrostatin and cell death was determined by PI positivity. TNFα 
can signal through either TNFR1 or TNFR2, initiating either cell death or cell survival 
response, respectively97, 98. We therefore used human TNFα (hTNFα) to maximize 
TNFR1-mediated cell death as hTNFα specifically initiates TNFR1, rather than TNFR2, 
signalling on murine cells99. As seen in Figure 7, hTNFα (80ng/ml) + IFNγ (30ng/ml) 
treatment increased PI positivity, not Annexin V positivity, compared with untreated 
cells. The addition of (4uM) Nec-1 was able recover this PI positivity. Conversely, the 
addition of (10uM) zVAD-fmk increased cell death substantially, which was again 
recovered partially by Nec-1. 
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Figure 7 – L929 cells undergo necroptotic cell death after TNFα treatment 
L929 cells were treated with 80ng/ml hTNFα and 30 ng/ml IFNγ in the presence or 
absence of 4uM Nec-1 and 10uM zVAD-fmk for 24 hours and cell death was 
determined using Annexin V and PI staining on FLOW cytometry analysis. 
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3.4 MVECs with RIPK1 inhibition are resistant to 
necroptotic death 
We next measured TNFα-induced necroptotic death in MVECs following treatment with 
TNFα. TNFα can signal through either TNFR1 or TNFR2, initiating either a cell death or 
cell survival response, respectively97, 98. Again, hTNFα was used to induce cell death. As 
shown in Figure 8A&B, we observed that MVECs treated with hTNFα (100ng/mL) + 
IFNγ (60ng/mL) increased cell death compared with untreated cells (PI positivity: 19.3 + 
2.1% in TNFα treated vs 9.4 + 1.6% in untreated cells, n=3, p=0.01). In order to 
modulate necroptotic death, the RIPK1 inhibitor necrostatin-1 (Nec-1) (10uM), and pan-
caspase inhibitor zVAD-fmk (60uM) were used. Addition of Nec-1 to hTNFα treatment 
reduced cell death to 12.5 + 5.1% PI positive (Figure 8A&B, n=3, p=0.09). However, 
zVAD-fmk+hTNFα treatment increased PI positivity to 25.9 + 2.7% (n=3, p=0.001), 
suggesting that increased PI positive cell death occurs only after the inhibition of 
caspases. Furthermore, zVAD-fmk induced cell death could be reversed by addition of 
the RIPK1 inhibitor Nec-1 (15.6 + 2.0%, n=3, p=0.02, Figure 8A&B), providing further 
evidence that a RIPK-mediated cell-death response occurs when caspase-mediated 
apoptotic pathways are blocked. These results suggest that MVECs are able to undergo 
TNFα induced cell death, which can be modulated by the inhibition of RIPK1. 
 
To further illustrate that the RIPK proteins regulate necroptosis and HMGB1 release, 
RIPK3 deficient MVECs were isolated from RIPK3-/- mice and treated with hTNFα and 
zVAD-fmk. PI positivity did not increase significantly following hTNFα treatment alone 
(6.5 + 3.0%, vs 7.3 + 2.3% in untreated cells, n=3, p=0.39) or after hTNFα treatment with 
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zVAD-fmk (7.5 + 1.1%, n=3, p=0.27, Figure 8C), suggesting that TNFR1 signaling 
cannot induce necroptosis following the deletion of RIPK3. 
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Figure 8 - RIPK1 and RIPK3 regulates necroptosis in MVECs 
MVECs from C57BL/6 wild type mice or RIPK3-/- mice were plated in equal 
numbers (105) and treated with 100ng/ml TNFα, 60uM zVAD-fmk or 10uM 
Nec-1 in serum free media. A) C57BL/6 MVECs death was measured by PI 
positivity after 48 hours using flow cytometry analysis. Histograms are 
representative of three experiments. B) Quantitated average of three 
independent cell death experiments from C57BL/6 MVECs (n=3, *: p < 0.05, 
**: p < 0.01). C). Quantitated average of three independent cell death 
experiments from RIPK3-/- MVECs (n=3, p > 0.05). 
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3.5 SMAC mimetics exacerbate TNFα mediated 
necroptosis 
Upon signaling TNFR1, TNFα can initiate either a cell survival or cell death response61. 
In an attempt to abrogate the pro-survival pathway following TNFR1 signaling, cIAP 
inhibiting SMAC mimetics were used to prevent up-regulation of NF-κB genes through 
the prevention of protein translation100. As seen in Figure 9, treatment with SMAC 
mimetic (100nM) + hTNFα (100ng/mL) increased the PI quadrants after just 6 hours. 
Addition of Nec-1 attenuated PI positive cell death, however, zVAD-fmk (10uM) was not 
able to exacerbate PI positivity, likely due to the low concentration added. 
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Figure 9 – SMAC mimetic exacerbates TNFα mediated necroptosis 
Wild type MVECs were plated in equal numbers (105) and treated with SMAC Mimetic 
(100nM), hTNFα (60ng/mL) in the presence and absence of Nec-1 (10uM) and zVAD-
fmk (50uM) and cell death was analysed using Annexin V and PI labeled flow 
cytometry analysis. 
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3.6 RIPK3 null MVECs are resistant to apoptotic and 
necroptotic death 
Since we were previously unsuccessful in initiating a cell death response in RIPK3-/- 
MVECs, we suspected that the removal of the necroptotic pathway may be preferentially 
initiating apoptosis, rather than necrosis after TNFα treatment. To test this, cells were 
treated with TNFα in the presence and absence of zVAD-fmk and stained with both 
Annexin V and PI. As seen in Figure 10A, RIPK3-/- cells treated with 100ng/mL hTNFα 
did not undergo significant increases in Annexin V positive or PI positive cell death, even 
after treatment with zVAD-fmk (60uM). However, super-physiological addition of 
600ng/mL hTNFα induced significant Annexin V positivity with no change in PI 
positivity, indicating an apoptotic response. This response could subsequently be 
recovered with the addition of zVAD-fmk (60uM), as seen in Figure 10B. These data 
indicate that RIPK3 null MVECs are indeed resistant to TNFα mediated necroptosis and 
preferentially undergo apoptosis after treatment with super-physiological amounts of 
hTNFα, which can be recovered with zVAD-fmk, a caspase-8 inhibitor. 
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Figure 10 – RIPK3-/- MVECs are resistant to apoptotic and nectoptotic cell death 
MVECs from RIPK3-/- wild type mice were plated in equal numbers (105) and treated 
with A) 100ng/ml TNFα, 60uM zVAD-fmk or 10uM Nec-1 in serum free media or B) 
600ng/ml TNFα, 60uM zVAD-fmk or 10uM Nec-1 in serum free media and cell death 
was measured by Annexin V and PI positivity after 48 hours using flow cytometry 
analysis. 
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3.7 RIPK1 inhibition or RIPK3 deficiency prevents to 
danger molecule HMGB1 release in MVECs 
Cells undergoing necrosis, not apoptosis or late apoptosis, release proinflammatory 
CDAMPs such as HMGB174, 101. We therefore measured cell-released HMGB1 in the 
supernatant of MVECs treated with hTNFα (100ng/mL) + IFNγ (60ng/mL) in the 
presence and absence of Nec-1 (10uM) or zVAD-fmk (60uM) using western blot analysis 
to confirm our findings in PI labelling cell death assays to verify the presence of necrotic 
cells. As expected, release of HMGB1 in TNFα treated MVECs correlated with the 
necroptotic pattern of cell death. Following treatment with zVAD-fmk and TNFα, 
HMGB1 release in MVEC supernatant increased significantly (band density: 8.33+3.61 
vs. 1 in untreated, n=4, p=0.02, Figure 11A&B). Addition of Nec-1 was able to attenuate 
HMGB1 release under anti-apoptotic conditions (intensity index 2.43+1.22, n=4, p=0.03, 
Figure 11A&B). These results indicate that HMGB1 release follows RIPK1 mediated 
necroptotic MVEC cell death. 
 
Similarly, there were no significant levels of HMGB1 detected in the supernatant of 
untreated RIPK3-/- cells and this remained unchanged following TNFα and zVAD-fmk 
treatment (Figure 11A). Therefore, RIPK3 deficiency, similar to RIPK1 inhibition, in 
MVECs also prevents TNFα induced-necroptotic death and HMGB1 release. 
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  Figure 11 – RIPK1 and RIPK3 regulate HMGB1 release in MVECs 
MVECs from C57BL/6 wild type mice or RIPK3-/- mice were plated in equal 
numbers (105) and treated with 100 ng/ml TNFα, 60mM zVAD-fmk or 
10mM Nec-1 in serum free media for 48 hours. (A) Supernatants collected 
from treated C57BL/6 MVECs and RIPK3-/- MVECs were analyzed for 
HMGB1 release by western blot. Equal volumes of supernatants were loaded 
for each treatment. As loading controls, remained C57BL/6 MVECs and 
RIPK3-/- MVECs were collected and the cytoplasmic lysates were used for 
detected the unreleased HMGB1 inside MVECs. (B) Western blot results 
were quantitated by densitometry analysis (Alpha View). Untreated MVECs 
were use as a reference. Quantitated average of three independent cell death 
experiments (n=3, *: p < 0.05). 
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3.8 RIPK3 regulates heart graft necrosis and HMGB1 
release after transplantation 
RIPK1 and RIPK3 are integral for the formation of the necrosome which leads to 
downstream necroptosis50, 60. However, knockout of RIPK1 in mice results in newborn 
lethality and therefore no model involving RIPK1 knockout exists in vivo102. To further 
investigate the effect of RIPK signalling in donor heart grafts, heterotopic heart 
transplantations were performed using wildtype C57BL/6 or B6 RIPK3-/- mice as donors 
and BALB/c mice as recipients. Recipient mice were given brief sirolimus treatment 
from day 0-9 to prolong heart survival91 and were sacrificed 12 days after transplantation. 
Upon sacrifice, heart grafts were collected for analysis of early tissue necrosis and 
apoptosis. In situ ethidium homodimer perfusion was performed as described in the 
methods to detect necrotic cells92. Heart grafts were examined for ethidium homodimer 
labelled areas (red) for necrosis using fluorescence microscopy. 
 
As seen in Figure 12A&B, H&E staining of wildtype and RIPK3-/- grafts showed 
increased lymphocyte infiltration localized primarily around the vessels in wildtype grafts 
compared with RIPK3-/- grafts (severity score: 3 + 0.6 in wildtype vs. 1.6 + 0.8 in RIPK3-
/- heart, n=5, p=0.01). Ethidium homodimer staining revealed that wildtype heart grafts 
had significantly higher levels of necrosis localized around the vessels of the heart 
compared with RIPK3-/- grafts (intensity index: 157.1 + 106.2 in wildtype vs. 12.1 + 9.5 
in RIPK3-/- heart, n=3, p=0.03) (Figure 12A&C), where staining was confined primarily 
to the endothelial barrier. TUNEL staining was used to detect apoptotic cells in situ and 
showed no significant differences between wildtype and RIPK3-/- heart grafts (5.5 + 5.7 
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in wildtype vs 1.6 + 2.4 in RIPK3-/-, n=3, p=0.09) (Figure 12A&E), suggesting that 
RIPK3 deficiency did not alter apoptosis in the graft compared with wild type mice. 
RIPK3 deficiency in RIPK3-/- naïve hearts was confirmed by western blot analysis 
(Figure 12D). In summary, these data suggests that RIPK3 deficiency protects heart 
grafts from necrotic death and endothelial damage post transplantation. 
  
49 
 
A 
  
H&E                         Ethidium                         TUNEL 
                         Homodimer 
Naïve 
Wildtype 
Heart 
 
 
Day 12 
Wildtype 
Heart 
Graft 
 
 
Day 12 
RIPK3-/- 
Heart 
Graft 
50 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
  
 
 
 
0 
1 
2 
3 
4 
Day 12 
Wildtype 
Day 12 
RIPK3-/- 
Infiltration 
* 
In
ju
r
y
  
S
c
o
re
 
E
th
id
iu
m
 
In
te
n
si
ty
 I
n
d
ex
 
 
 
 
 
0 
5 
10 
15 
20 
25 
Wildtype RIPK3-/- 
* 
RIPK3 
(57 kDa) 
 
actin 
Wildtype   RIPK3-/- 
51 
 
E 
  
 
 
 
 
 
0 
2 
4 
6 
8 
10 
12 
Wildtype RIPK3 -/- 
TU
N
EL
 
In
te
n
sit
y 
In
de
x
 
52 
 
  
Figure 12 – RIPK3 deficiency reduces necrosis and graft infiltration following heart 
transplantation 
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were heterotopically transplanted into 
BALB/c recipients. Sirolimus (1mg/kg) was given from operative day 0 to post-operative 
day 9 and heart grafts were collected at post-operative day 12. A) Graft tissue obtained 
was formalin fixed at the time of sacrifice and stained by H&E, ethidium homodimer or 
TUNEL assay. Data is representative of five transplanted grafts. Areas of greatest injury 
are shown in both wildtype and RIPK3-/- grafts. B) Blinded quantitative pathological 
scoring of cellular infiltration in wildtype and RIPK3-/- grafts. Slides were scored on a 
scale from 0-4 as described in the methods (n=5, *: p <0.05). C) Quantification of 
ethidium homodimer fluorescence staining for necrosis in wildtype and RIPK3-/- heart 
grafts 12 days following transplantation (n=3, *: p < 0.05). D) Quantification of TUNEL 
staining for apoptosis in wildtype and RIPK3-/- heart grafts 12 days following 
transplantation (n=3, ns: p>0.05). E) Western blot analysis of wildtype and RIPK3-/- heart 
grafts for expression of RIPK3 protein.  
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3.9 HMGB1 release is attenuated in RIPK3 null allografts 
following cardiac transplantation 
As mentioned previously, necrosis results in the release of proinflammatory HMGB174, 
101
. Interestingly, HMGB1 released following necrotic cell death can exist in an 
immunogenically active form, whereas cells undergoing apoptosis can release a tolerance 
promoting (oxidized) form103. We therefore measured HMGB1 in heart graft lysates 
isolated by cytoplasmic lysis buffer at day 12 following transplantation. Western blot 
analysis revealed that only the active form of HMGB1 increased in wildtype grafts, but 
not in RIPK3-/- grafts (Intensity index: 0.99 + 0.22 in wildtype vs. 0.64 + 0.19 in RIPK3-/-
, n=5, p=0.03, Figure 13A&B). Interestingly, the (lower) oxidized band of HMGB1 
remained statistically similar between wildtype and RIPK3-/- grafts (0.34 + 0.19 in 
wildtype vs. 0.35 + 0.13 in RIPK3-/-, n=5, p=0.12, Figure 13A&B).  
 
Immunohistochemistry for HMGB1 revealed increased HMGB1 release from the nucleus 
of cardiomyocytes surrounding the vessels (red arrows) in wildtype grafts compared with 
RIPK3-/- grafts (Figure 13C). Released HMGB1 can be seen diffusely in the cytoplasm of 
injured cells. Taken together, these data further support the notion that deficiency of 
RIPK3 provides a protective role against necroptotic death and subsequent HMGB1 
release in heart grafts.  
 
Lastly, we measured the chemokine expression levels in wildtype and RIPK3 null grafts 
12 days following transplantation, as shown in Figure 13D. Compared with naïve, 
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untreated C57BL/6 hearts, wildtype grafts expressed higher transcript levels of CXCL10 
(26.5 + 27.6 fold increase in wildtype vs 13.2 + 13.2 in RIPK3-/-, n=5, p=0.2), CCL3 
(30.9 + 53.7 fold increase in wildtype vs 9.5 + 8.5 in RIPK3-/-, n=5, p=0.24), 
RANTES(8.1 + 14.9 fold increase in wildtype vs 1.2 + 2.0 in RIPK3-/-, n=5, p=0.21) and 
MCP-1 (31.3 + 55.1 fold increase in wildtype vs 1.63 + 1.8 in RIPK3-/-, n=5, p=0.17)  
than RIPK3 null grafts. However, these differences were non-significant. 
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Figure 13 – RIPK3 deficiency inhibits danger molecule HMGB1 release and 
inflammatory responses in the heart graft 
Protein from heart grafts collected 12 days following heart transplantation as 
described in Figure 12 were isolated by cytoplasmic lysis buffer before being 
examined for HMGB1. A) Western blot analysis of HMGB1 in naïve and 
transplanted wildtype and RIPK3-/- hearts. Separate bands represent the amount of 
immunogenic (upper band) or oxidized forms (lower band) of HMGB1. Data shown 
is representative of five transplanted grafts. B) Densitometry analysis of 
immunogenic and oxidized HMGB1 (n=5, *: p<0.05). β-actin was used as a loading 
control and quantitation reference. C) Paraffin fixed sections were stained for total 
HMGB1in both wild type and RIPK3-/- hearts. Areas of HMGB1 being released into 
the cytoplasm and in nuclei undergoing harryorrhexis are indicated by arrows. D) 
cDNA was isolated from heart grafts collected 12 days following heart 
transplantation and analysed by RT-qpPCR for chemokine expression. Values are 
representative of five separate experiments. 
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3.10 RIPK3 deficiency in heart allografts prolongs graft 
survival after transplantation following sirolimus treatment 
To determine if RIPK1/3 mediated necroptotic death could influence cardiac transplant 
survival, we performed heterotopic transplantation of wildtype C57BL/6 or B6 RIPK3-/- 
donor hearts into fully MHC mismatched recipient BALB/c mice. As shown in Figure 
14A, without immunosuppressive treatment, RIPK3 null heart grafts have similar 
survival times compared to wildtype grafts (10+0.8 days in wildtype vs. 10.3+0.5 days in 
RIPK3-/-, n=4). However, treatment with sirolimus (1mg/kg) from surgical day 0 to day 9 
extended the survival time of wildtype grafts to 24 + 2.6 days and RIPK3-/- grafts to 95 + 
5.8 days (n=4, P=0.011). As shown in Figure 14B, naïve C57BL/6 hearts do not appear 
histologically different from naïve RIPK3-/- hearts, but wildtype heart grafts show severe 
lymphocyte infiltration and vasculopathy at rejection day compared with RIPK3-/- grafts 
collected on day 40. RIPK3 was also detected in the endothelium and cardiac myocytes 
of naïve wild type hearts, but not RIPK3-/- hearts, by immunohistochemistry. This data 
indicates the absence of RIPK3 in heart grafts can greatly prolong graft survival, 
suggesting that RIPK3 mediated necroptotic death has a deleterious effect on heart graft 
survival.  
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  Figure 14 – RIPK3 deletion in donor grafts induced long term graft survival 
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were transplanted into BALB/c 
recipients. Sirolimus (1mg/kg) was given daily from operative day 0 to post-
operative day 9. Graft survival was monitored daily by palpitation. Significant drop 
or cessation of pulsation is considered as graft rejection. A) Survival curve of 
wildtype C57BL/6 and RIPK3-/- donor heart grafts in BALB/c mice was obtained 
from two repeated experiments with and without sirolimus treatment (n=4, *: p < 
0.05, Log rank test). B) RIPK3 detection in heart grafts and H&E comparison of 
wildtype and RIPK3-/- grafts. Heart grafts were collected from wild type recipients 
24 days after transplantation and RIPK3-/- graft recipients 40 days after 
transplantation and fixed by formalin before H&E staining or 
immunohistochemistry analysis by anti-RIPK3 (Abcam).  
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3.11 CD40 costimulatory blockade does not extend RIPK3 
null graft survival following cardiac transplantation 
Cardiac allograft transplantation was again performed using wildtype and RIPK3-/- donor 
grafts with a single treatment of MR1 (200ug) one day before transplantation. In both 
wildtype and RIPK3-/- grafts, rejection began at post-operative day 20 and is shown 
histologically in Figure 15A. Pathological scoring during rejection revealed no significant 
differences in endothelial damage, necrosis, infiltrate or myocyte damage (n=2) between 
wildtype and RIPK3-/- grafts, as shown in Figure 15B. 
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  Figure 15 – RIPK3 deletion does not protect heart grafts following CD40 
costimulatory blockade 
Wildtype C57BL/6 or B6 RIPK3-/- donor hearts were transplanted into BALB/c recipients. 
Anti-CD154 (200ug) was given daily from operative day 0 to post-operative day 9. Graft 
survival was monitored daily by palpitation. Significant drop or cessation of pulsation is 
considered as graft rejection. A) Wild type and RIPK3-/- grafts were examined using H&E 
staining and confocal microscopy (400X) following rejection after day 20. B) Blinded 
pathological scoring of rejected grafts for endothelial damage, necrosis, infiltrate and 
myocyte damage (n=2, p > 0.05). 
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Chapter 4  
4 Discussion 
4.1 Summary of this study 
In this study, we isolated, immortalized and characterized a new murine MVEC cell line 
for in vitro experimental use (Figure 5). We have shown at the mRNA and protein level 
that RIPK3 can be upregulated by TNFα and that TNFR1 can be upregulated by both 
TNFα and/or IFNγ in MVECs (Figure 6). Necroptotic death and subsequent danger 
molecule HMGB1 release were also observed in wildtype MVECs under anti-apoptotic 
conditions, which could be significantly attenuated following pharmacological RIPK1 
inhibition or RIPK3 knockout (Figures 8 and 11). We also observed that RIPK3 null 
MVECs underwent apoptosis following super-physiological treatment of TNFα, which 
could be partially recovered by caspase inhibition (Figure 10). Following cardiac 
allograft transplantation, RIPK3 null donor grafts survived significantly longer following 
sirolimus treatment than wild type donor grafts (Figure 14). Following transplantation, 
RIPK3 null grafts showed significantly less host immune infiltration and necrosis 
compared with wild type grafts while maintaining similar levels of apoptosis (Figure 12). 
Lastly, protein levels of danger molecule HMGB1 were attenuated in RIPK3 null 
allografts shortly following transplantation (Figure 13). The ability of 
immunosuppression to provide rejection protection is dependent on the cell death pattern 
of the graft following transplantation. We suggest that targeting proteins RIPK1 or 
RIPK3 in heart grafts may be beneficial in future transplantation therapies. 
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4.2 Inflammatory injury, cellular rejection and cell death 
In clinical cardiac transplantation, injury and inflammation can result in delay or loss of 
graft function and reduced survival rates following transplantation. Mechanisms of 
injury, such as IRI, commence early in the transplantation procedure, while others 
continue throughout the life of the graft, such as chronic cellular rejection and GVD. 
These mechanisms of injury initiate different forms of cell death in graft parenchymal 
and endothelial cells, including apoptosis, autophagy and necrosis, which may influence 
the outcome of the graft through inflammatory sequelae. 
 
Cardiac transplantation invariably results in damage to the transplanted organ beginning 
with organ procurement, storage, surgical manipulation, ischemic time and reperfusion 
injury. These necessary procedures can often influence long-term graft survival through 
early up-regulation of alloantigens and cell adhesion molecules, leading to accelerated 
allorecognition104. IRI can result in apoptotic, autophagic and necrotic cell death, 
subsequently initiating host immune responses and the promotion of antibody and cell 
mediated rejection86, 105-107. These various forms of cell death potentially have important 
implications on the severity of the immune responses following transplantation and can 
greatly influence early and chronic survival of the graft.  
 
Following IRI, cardiac grafts are susceptible to ACR, which constitutes one of the most 
frequent causes of profound graft tissue damage within the first year after transplantation. 
Acute injury is often an adaptive immune response initiated following the maturation of 
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recipient CD4+ helper T cells, CD8+ cytotoxic T cells and B lymphocytes. These cell 
types can attack the graft through direct or indirect allorecognition pathways. 
 
Chronic cardiac allograft rejection presents as GVD, a severe, diffuse vascular intimal 
hyperplasia with eventual stenosis of the vascular wall resulting in compromised vascular 
flow and ischemia. It is unclear whether the incidence of ACR can affect long term graft 
survival by accelerating GVD through early allorecognition. Many studies have 
positively correlated ACR and GVD108-110, however, others have failed to find a direct 
correlation between biopsy-confirmed acute rejection and GVD111-113. Instead, GVD 
seems to result from any cellular insult including IRI9, 12-14, indirect allorecognition by 
CD4+ T cells17 and cytokine release15, 16. 
 
In clinical transplantation, the short-term success rate of allografts has steadily improved 
over the decades while long-term graft attrition has remained constant1, 114-116. 
Improvements in short-term transplant success can be attributed to improved 
immunosuppressive management of acute rejection episodes, organ preservation, donor 
selection, biopsy management and techniques, and diagnosis and management of 
infection. However, despite our increased knowledge of immunobiology and improved 
immunosuppressive therapies, long-term functional survival times of cardiac allografts 
remains stagnant and thus transplantation has remained a treatment, rather than a cure, for 
devastating cardiac events. In this study, we attempt to augment cell death in the donor 
graft through inhibition or deletion of the RIPK proteins, which are critical in the 
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initiation of necroptotis, a cell death pathway that enhances rejection initiating immune 
responses.  
 
Apoptotic cell death has been extensively studied in cancer, infectious disease, 
autoimmune disease and transplantation117, 118. Apoptosis leads to the formation of 
annexin-V positive apoptotic bodies that sequester cellular contents and are rapidly 
eliminated via phagocytosis by other cells with minimal inflammation117, 118. This process 
is initiated following the activation of caspases, a series of highly regulated endogenous 
cysteine proteases. Some caspases are pro-inflammatory, such as caspase-1, which 
localizes in inflammasomes to process IL-1β and IL18119, while others require death 
receptor engagement. The death receptor pathway is induced by TNFR super-family 
members (TNFR1, Fas, TRAIL) and requires the activation of caspase 8 to initiate 
apoptosis. Traditionally, apoptosis was thought to be a neutral factor in transplantation 
due to its non-immunogenic properties. However, recent studies have proved otherwise. 
Endothelial cell apoptosis has been shown to be an immunoregulatory process that is 
important in GVD related intimal remodelling120, 121, while the release of “find me” and 
“eat me” signals by apoptotic cells has been shown to recruit macrophages and 
monocytes122-124. In addition, apoptotic cells not cleared by the immune system may 
undergo secondary necrosis with subsequent plasma membrane permeation and release of 
CDAMPS, similar to necrosis or necroptosis117. 
 
Necrosis was traditionally regarded as an unregulated means of cell death as a result of 
unexpected cellular stresses. Recently, it has been observed that the death receptors 
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TNFR1 or Fas, when engaged, can elicit necrosis as well as apoptosis64, 125, 126, 
suggesting necrosis can also be regulated by signal transduction pathways. This regulated 
form of caspase-dependent necrosis has now been termed necroptosis and is controlled by 
RIPK1 and RIPK359, 69, 80, 126.Necroptosis is characterized by the same morphological 
features as unregulated necrotic death, including early loss of plasma membrane integrity 
and release of cytoplasmic contents127. These contents, such as immunogenic CDAMPS, 
can bind to immune cell receptors and initiate powerful immune responses75.  
 
In this study, necroptosis was induced in vitro using TNFα. TNFα is a proinflammatory 
cytokine produced by graft infiltrating cells, endothelial cells, and cardiac myocytes. 
TNFα quickly increases in cardiac grafts after transplantation43, 45 and has been shown to 
be an important contributor of heart graft rejection44-46, 48, 128. In addition, TNFα blockade 
or TNFR deficiency has been shown to prolong cardiac graft survival in several animal 
models44, 46, 47. TNFα induces death through TNFR1 but promotes pro-inflammatory 
responses through TNFR2129. 
 
Interestingly, myocardium in human donor heart grafts can modulate TNFR expression 
following rejection related injury by radically down-regulating TNFR1 and up-regulating 
TNFR2 surface expression following heart transplantation48. Conversely, human and 
murine endothelial cells do not undergo radical changes in TNFR1 expression patterns 
before and post transplantation48 and therefore are susceptible to TNFα induced cell 
death. As the first barrier between graft and host, MVEC’s undergoing early necroptotic 
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death may promote cardiac graft inflammation and subsequently augment rejection 
responses. Here we have shown that inhibition of caspase function enhanced necrotic cell 
death and the release of HMGB1 in endothelial cells and inhibition of RIPK1 or RIPK3 
function attenuated necroptotic death (Figure 8 A-C) and subsequent danger molecule 
HMGB1 release (Figure 11A&B). RIPK3 deficiency in donor heart allografts prevented 
endothelial necrotic death, HMGB1 release, and substantially prolonged graft survival 
after short-term sirolimus treatment. This study suggests that RIPK1/3-mediated 
necroptosis contributes to inflammatory injury in cardiac allografts and that RIPK1 and 
RIPK3 are important therapeutic targets to induce long term graft survival. 
 
4.3 The pattern of cell death can be differentiated using 
pharmacological inhibitors or genetic modification 
In recent years, our understanding of cell death has expanded beyond apoptosis, 
autophagy and necrosis and now includes regulated necrosis which comprises RIPK 
mediated necroptosis, pyronecrosis, excitotoxicity, pyroptosis, parthanatos, NETosis, 
entosis, ferroptosis, anoikis, lysosomal membrane permeabilization, Wallerian 
degeneration and heat-stroke-induced regulated necrosis130. Consequently, various forms 
of cell death detection have arisen to differentiate between cell death forms. These 
methods include quality of DNA fragmentation, morphology, cell viability, caspase 
activation, PARP1 cleavage, and labeling with Annexin or PI, among others. However, 
these methods alone are often non-definitive and often require conjunction with 
inflammatory markers and the use of pathway-specific pharmalogical inhibitors, RNA 
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knockdown or animal models with genetic deletion to confirm a specific cell death 
pathway75, 131.  
 
In this study, PI labeling was used in vitro to identify necroptotic cell death, a method 
previously used in many studies49, 50, 60, 65, 86, 132, 133, while others have used annexin-V 
labeling to detect necroptotic death 69, 133-135. PI is an intercalating agent and binds to 
DNA inside the nucleus of cells. This requires the loss of plasma membrane integrity as 
PI cannot permeate healthy cell membranes. Annexin V binds phosphatidylserine, 
making it a useful marker for detecting apoptosis following the apoptotic plasma 
membrane translocation of phospholipids136. Sawai and colleagues, using a human 
monocyte leukemia cell line, U-937, have previously shown that necroptotic cells can 
label as annexin V positive / PI negative, annexin V negative / PI positive, or annexin V 
positive / PI positive137. However, their data only shows PI positive labeling in anti-
apoptotic conditions after zVAD-fmk treatment, an important pro-necroptotic condition. 
Furthermore, their conclusion that necroptotic cells could label as annexin V positive / PI 
negative was based on the observation that Nec-1 could recover annexin V positive / PI 
negative cell death. Although it is known that PI positivity can result from secondary 
necrosis following apoptosis137, PI labeling while augmenting cell death using zVAD-
fmk, Nec-1 and RIPK3-/- MVECs in conjunction with the release of the inflammatory 
marker HMGB1 is sufficient evidence of necroptosis. 
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Necroptosis becomes the predominant form of cell death when caspase 8-mediated 
apoptotic pathways are blocked and can be reverted to apoptosis in the presence of RIPK 
inhibition64, 138, 139. Hence, caspase-8 is not only an inducer of apoptosis, but also an 
inhibitor of necroptosis as it has been observed that caspase-8 deficiency leads to 
unregulated necroptosis in the yolk sack vessels of developing embryos, resulting in early 
embryonic lethality140-142. Therefore, blocking apoptotic regulators, particularly caspase 
8, may not benefit heart graft survival as it may enhance necroptosis and worsen 
inflammatory injury in the graft. Alternatively, targeting RIPK proteins would inhibit 
necroptosis and thus minimize graft injury. Vercammen and colleagues showed the 
profound effects of zVAD-fmk in L929 fibroblasts on necroptotic death. In their 
experiments, the half-maximal dose of TNFα needed to induce necroptosis was decreased 
by a factor of 1000 in the presence of zVAD-fmk and exogenous TNFα over TNFα 
alone50. Since these findings were published, zVAD-fmk has been used in several studies 
to induce necroptosis54, 63, 69, 84, 135, 143. This mechanism was discovered to be prominent 
in mouse L929 fibroblasts49 and was confirmed in this study (Figure 7).  
 
4.4 HMGB1 as a marker for necroptosis and inflammation 
Necrosis results in inflammatory sequelae mediated by the release of cell contents 
including HMGB1, heat-shock proteins, histones, uric acid, RNA, and DNA, all of which 
can trigger inflammatory reactions74-76. HMGB1, which augments expression of 
chemokines and cytokines that attract and activate diverse immune cells through binding 
on its receptors TLR-2 or -4, has been shown to participate in early heart injury and 
further augments adaptive immune responses during graft rejection75, 76, 144.  Importantly, 
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HMGB1 is mainly released from necrotic, but not apoptotic or late apoptotic cells, which 
results in pro-inflammatory responses74. In our study, HMGB1 was used to confirm 
necroptotic cell death in conjunction with PI labeling, which may bind late apoptotic and 
secondary necrotic cells. Indeed, we found that necroptosis-induced HMGB1 release was 
substantially inhibited in RIPK3 deficient MVECs or by inhibiting RIPK1 with Nec-1 
(Figure 11A&B). This finding was further supported by the results of our in vivo study 
where the release of HMGB1was inhibited in RIPK3-/- heart grafts compared with wild 
type heart grafts (Figure 13A&B). However, a challenge arose in finding a method of 
quantifying necrotic cell death in vivo to correlate cell death and HMGB1 release in heart 
grafts. Previous studies have relied on microscopy and pathological scoring, which are 
susceptible to high degrees of inter-observer variability. To address this, we modified a 
protocol of ethidium homodimer perfusion into a mouse kidney92 for application in a 
heterotopic heart. Ethidium homodimer, similar to PI, binds DNA after cell membrane 
rupture. In the heterotopic heart, ethidium homodimer staining of the endotheilium and 
cardiomyocytes indicated the level of vascular damage, leakiness and myocyte necrosis. 
Consequently, we found that ethidium homodimer staining and lymphocyte infiltration 
were significantly greater in wild type mice 12 days after transplantation than RIPK3-/- 
heart grafts (Figure 12A-C). In addition, immunohistochemistry in heart graft sections 
revealed increased HMGB1 staining in cellular nuclei undergoing karyorrhexis and in the 
cytoplasm of cardiomyocytes (Figure13C). Finally, compared with wildtype donor grafts, 
RIPK3 deficiency in donor heart grafts induced long term graft survival following short-
term sirolimus treatment (Figure 14A). These data suggest that RIPK3-mediated 
necroptosis contributes to the release of the danger molecule HMGB1 and subsequently 
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enhances inflammatory injury in heart allografts. Hence, RIPK1/3-mediated necroptosis 
and subsequent inflammatory responses play a reciprocal role for heart graft rejection. 
Inhibiting the feedback loop of TNFα, RIPK, HMGB1 and infiltrating immune cells may 
prevent graft injury and promote long term graft survival.   
 
4.5 HMGB1 subtypes influence immune responses 
Previous research suggests that different forms of HMGB1 can be released during cell 
death103, 145. The active form of HMGB1 released from necrotic cells has an 
immunogenic function through TLR interaction, whereas cells undergoing apoptosis 
release a tolerogenic form of HMGB1whose stimulatory function is neutralized after 
oxidization103. More recently, a third form of HMGB1, all-thiol-HMGB1, has been 
shown to exist and acts as a chemoattractant to recruit leukocytes. In our study, wild type 
heart grafts 12 days after transplantation have much higher levels of the active form of 
HMGB1 than RIPK3-/- grafts (Figure 13A&B). Binding of this form of HMGB1 to TLR-
4 and RAGE receptors promotes T cell, macrophage and DC maturation, exacerbating 
cellular mediated graft rejection. There were no differences in levels of the oxidized form 
of HMGB1 between wild type and RIPK3 null heart grafts, indicating that apoptosis in 
heart grafts was not altered by RIPK3 deficiency. This finding was supported by heart 
tissue TUNEL staining, which showed no significant differences in apoptotic area in 
heart grafts compared wild type and RIPK3-/- mice (Figure 13A&E). However, the 
presence of oxidized HMGB1 in heart grafts contrasted the HMGB1 profile in MVECs in 
vitro, where only the immunogenic form of HMGB1 was detected by western blot 
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following MVEC necroptosis. In this instance, the oxidized form of HMGB1 seen in vivo 
may have originated from host infiltrating cells146 or other heart cells. The third form of 
HMGB1 has yet to be identified via western blot but likely contributed to graft rejection 
via a chemotactic funciton145. Additionally, no significant changes were seen in the 
expression of chemokines between wild type and RIPK3-/- grafts. Nonetheless, both our 
in vitro and in vivo results further support the notion that necroptosis results in the release 
of danger molecule HMGB1 and augments graft rejection in transplantation. In contrast, 
apoptosis will result in decreased danger molecule release and minimize cell death-
induced inflammatory responses in heart graft. Hence, programmed apoptotic cell death, 
rather than necroptotic cell death, may be beneficial for heart graft survival.  
 
4.6 Cardiac allograft survival and immunosuppressive 
management 
In clinical transplantation, proper immunosuppressive management is critical in 
preventing both acute and chronic rejection. Several immunosuppressive regimens 
currently exist in the clinic, many of which inhibit T cell survival, activation and clonal 
expansion. This outcome is achieved by targeting molecular pathways involved in T cell 
recognition of foreign antigens, costimulatory pathway activation and the production of 
IL-2. Clinically, drugs such as tacrolimus, sirolimus and thymoglobulin are used to 
prevent T cell proliferation, while costimulatory blockades have been successful in pre-
clinical trials but have not yet been used clinically. 
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In this study, wild type C57BL/6 and RIPK3-/- heterotopic donor cardiac grafts were 
transplanted into recipient Balb/c mice followed by short-term sirolimus treatment. Using 
this model, we observed significant improvements in graft survival in both wild type and 
RIPK3-/- donor hearts compared with untreated grafts. Furthermore, we observed 
significant increases in graft survival time, cellular necrosis and lymphocyte 
inflammation in RIPK3-/- grafts compared with sirolimus treated wild type grafts (Figure 
14A&B). This data provides evidence that the efficacy of immunosuppression is 
dependent on the pattern of cell death in the graft and the removal of immunogenic 
necroptosis benefits heart graft survival.  
 
However, it is possible that the deletion of RIPK3 in donor grafts may affect other cell 
death pathways, such as apoptosis and autophagy. Indeed, we observed significant 
resistance of RIPK3-/- MVECs to apoptosis following hTNFα treatment (Figure 10). 
Furthermore, augmentation of cell death pathways may be further influenced by the 
chosen method of immunosuppression. Previous groups have reported the induction of 
cellular autophagy following sirolimus treatment in many mouse models147-149. The 
induction of autophagy by sirolimus could potentially benefit long-term graph survival, 
sparing the graft from apoptotic and immunogenic necroptotic death.  Therefore, the 
beneficial effect of sirolimus in heart cells needs further investigation, despite only 
treating with sirolimus for 9 days after transplantation. Alternatively, we transplanted 
wild type and RIPK3-/- hearts into Balb/c recipients using anti-CD154 costimulatory 
blockade to inhibit T cell responses. A sub-therapeutic dose of 200ug anti-CD154 
antibody was used since Zhang and colleagues have previously shown a 250ug single-
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dose treatment of anti-CD154 induces a 40% acceptance rate after 100 days in wild type 
grafts150. However, RIPK3-/- grafts treated with 200ug of anti-CD154 showed no 
differences in survival or lymphocyte infiltration (Figure 15A&B). Future studies should 
use a 250ug dose to compare the 40% wild type acceptance rate to that of RIPK3-/- grafts. 
 
These results indicate that the method of immunosuppression may be important during 
graft-targeted therapy. However, retrospective consideration of the tolerance inducing 
mechanism of our RIPK3-/- model versus that of anti-CD154 therapy leads us to believe 
that the tolerance inducing mechanism in each model is mutually exclusive. As 
mentioned previously, the CD40/CD154 interaction has important implications in plasma 
cell antibody type switching and absence of CD40 or inhibition of CD154 results in 
hyper-IgM syndrome28. As RIPK3 mediated necroptosis is initiated by TNFα or Fas 
binding to cellular receptors, disruption of immunoglobulin class switching should have 
no effect on the survival of RIPK3-/- grafts. Although CD40/CD154 is known to affect T 
cell activation, the mechanism is indirect via the upregulation of CD80 or CD86 on APCs 
and may not greatly affect TNFα production by CD4+ T cells. Furthermore, anti-CD154 
treatment alone is known to induce only acute rejection protection, and not chronic 
rejection protection, in heart allograft models30, 151. Instead, anti-CD154 treatment is 
recommended to be used in conjunction with sirolimus to promote long-term tolerance 
and prevent chronic rejection152. In either model, robust cellular and humoral immune 
responses quickly cause cell death within the graft. Immunosuppressive therapies 
currently prevent early graft rejection, but chronic rejection still can occur through the 
slow and steady destruction of heart cells over time. Therefore, the RIPK1/RIPK3 
78 
 
mediated death pathway is more relevant in chronic, rather than acute, rejection. Future 
studies using treatment with CTLA4Ig, which directly blocks CD28 activation on T cells, 
may have be a more effective method of demonstrating the advantage of RIPK3-/- grafts. 
Nonetheless, anti-CD154 and CTLA4Ig treatment have not been successfully transferred 
into clinical therapy. This study may provide a sound rationale that using clinically 
relevant drugs such as sirolimus, tacrolimus, or thymoglobulin in conjunction with donor-
specific anti-cell death therapy for future patient treatment. 
 
4.7 Conclusion 
In this study we have demonstrated that RIPK3 and TNFR1 expression on MVECs can 
be regulated by TNFα and IFNγ. We have shown for the first time in MVECs that 
caspase 8 plays a protective role against RIPK1 and RIPK3 mediated necroptosis as 
blockade of caspase 8 exacerbates, while inhibition of RIPK1 or RIPK3 abrogates, 
necroptotic death. We have also shown that danger molecule HMGB1 release correlates 
with necroptotic cell death in MVECs. Furthermore, following heterotopic heart 
transplantation, deletion of RIPK3 in donor hearts ameliorates necrotic death, 
inflammation and HMGB1 release in the donor graft, leading to prolonged survival. 
Inhibition of RIPK1 or RIPK3 in transplant patients may therefore protect the donor heart 
graft from necroptosis, decreasing graft immune infiltration and the release of 
proinflammatory danger signals that lead to chronic allograft injury. 
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4.8 Future direction 
We recommend that future studies explore the clinical importance of necroptosis in 
transplantation through the use of clinically relevant immunosuppressive therapies such 
that this treatment may be brought from bench to bedside. This includes developing 
methods of graft specific targeting of proteins RIPK1 and RIPK3, perhaps during donor-
to-recipient transfer, and determining the effect of RIPK1/RIPK3 inhibition on other 
forms of cell death following immunosuppression. 
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